These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38583450)

  • 1. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
    Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
    Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Tascilar K; Hagen M; Kleyer A; Simon D; Reiser M; Hueber AJ; Manger B; Englbrecht M; Finzel S; Tony HP; Schuch F; Kleinert S; Wendler J; Ronneberger M; Figueiredo CP; Cobra JF; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Kruger K; Henes J; Schett G; Rech J
    Lancet Rheumatol; 2021 Nov; 3(11):e767-e777. PubMed ID: 38297524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
    van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ
    Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
    Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
    Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA).
    Jung SM; Pyo JY; Lee SW; Song JJ; Lee SK; Park YB
    Semin Arthritis Rheum; 2020 Dec; 50(6):1414-1420. PubMed ID: 32241617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
    Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
    de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
    Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
    van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP
    Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
    Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
    J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
    Fautrel B; Den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):550-65. PubMed ID: 26697766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.